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Abstract 
 
It is increasingly evident that micronutrient environment experienced before birth and in infancy is 
important for achieving optimal bone mass by adolescence and maintaining bone health. This study 
determined whether maternal supplementation with omega-3 polyunsaturated fatty acids (n3FA) 
improved offspring bone growth and adult bone mass.  Female rats were fed a diet containing 0.1% 
(Control, n=10) or 1% (n3FA, n=11) docosahexanoic acid (DHA) during pregnancy and lactation.  
Offspring were weaned onto a control diet. Tibial growth plate and metaphysis structure, 
osteoblast/osteoclast density and differentiation, and gene expression were assessed in offspring at 3 
weeks (weaning), 6 weeks (adolescent) and 3 months (adult). Maternal n3FA supplementation 
elevated offspring plasma n3FA levels at 3- and 6-weeks. While total growth plate heights were 
unaffected at any age, the resting zone thickness was increased in both male and female offspring at 3 
weeks.  In n3FA males, but not females, bone trabecular number and thickness were increased at 3 
weeks but not other ages. The week-3 n3FA males also exhibited an increased bone volume, an 
increased osteoblast but decreased osteoclast density, and higher expression of osteoclastogenesis 
inhibitor OPG but lower expression of osteoclastogenic cytokines RANKL, TNF-α and IL-6. No 
effects were seen at 6 weeks or 3 months in either sex. Thus, perinatal n3FA supplementation is 
associated with increased bone formation, decreased resorption and a higher bone mass in males, but 
not in females, at weaning; these effects do not persist into adolescence and adulthood and are 
unlikely to produce lasting improvements in bone health. 
 
INTRODUCTION 
Osteoporosis has long been recognised as a problem of older adults, however poor bone health is now 
being seen increasingly in children and adolescents (1). For example, low bone mass and/or more 
frequent fractures are commonly seen in children or adolescents suffering from poor nutrition or 
micronutrient deficiency (2).  Whilst seventy-five to eighty percent of peak bone mass attained by an 
individual is attributed to genetics, 20-25%  is related to life style and environmental factors, in 
particular nutrition (3). In addition to the role of nutrition in determining adult bone health, previous 
research has also shown that the nutrient supply before birth and into early infancy is important in 
determining the health outcomes of offspring into adulthood (4, 5), including bone mass (6). In 
addition, it is well documented that malnutrition or under-nutrition during critical growth periods in 
childhood can cause growth retardation and decreased bone formation. This, in turn, reduces the peak 
bone mass attained in adolescence (7-10), which is known to be an important determinant of bone 
mass/strength throughout later life (11).  Therefore it is evident that nutritional strategies that can be 
applied during critical periods of bone growth during early infancy, childhood and adolescence are 
important in order to  achieve optimal bone growth and peak bone mass and  ensure good bone health 
and prevention of osteoporosis in adult life. Thus, devising effective strategies for optimising bone 
health during early life is important not only for achieving optimal childhood bone health, but for 
minimising/delaying onset of ageing-related osteoporosis and fractures (12). 
 
In addition to an adequete supply of overall energy, optimal growth and development of the human 
skeleton and maintenance of bone health also requires an adequate supply of specific macronutrients,  
micronutrirents as well as bioactive ingredients, including protein, inorganic minerals (e.g., calcium, 
magnesium, phosphorus), vitamins (vitamins A, D, E, K, C), and long chain omega-3 polyunsaturated 
fatty acids (n3FAs) (13). Although not classically associated with bone development, there is 
accumulating evidence that the supply n3FAs during critical periods of bone growth can also play an 
important role in optimizing bone health and bone mass.   
 
A number of studies have demonstrated that, in addition to their well-established effects on cardiac 
health and anti-inflammatory properties, n3FAs also have positive effects on bone development and 
metabolism.   Dietary supplementation with n3FAs increased bone density and bone strength in adult 
rats and piglets (14-16).  In growing rats, n3FAs increased osteoblast formation and activity resulting 
in an increased rate of bone formation, suggesting that n3FAs may be linked to an alteration in 
osteoblast formation and/or function (17, 18). Apart from promoting bone formation, n3FAs also 
inhibit bone resorption in adult rats by suppressing expression of inflammatory cytokines and NF-B 
activation and thereby reducing osteoclast formation and activity (19, 20). There is also evidence that 
n3FA supplementation is beneficial for bone health in humans, and n3FA supplementation has been 
shown to promote bone health by suppressing bone resorption (21) and improving bone density in 
older adults and postmenopausal women (21-24).  Together these findings indicate that n3FAs exert a 
positive effect on bone formation and metabolism, which could represent a potential nutrition 
supplementary strategy that could be explored for improving bone growth and increasing bone mass.  
 
Due to compliance and delivery issues encountered with children, delivery to the mother, rather than 
the child would represent a more practical means of delivering n3FAs to the fetus and breast-fed 
infacts to improve offspring bone development and growth.  A number of large scale clinical trials 
have confirmed that maternal n3FA supplementation is safe for both the mother and the infant, and 
may have benefiical effects on infant cognitive development (25, 26). However, there are no studies 
to date which have determined whether exposure to an increased supply of n3FA during the perinatal 
period, i.e. a critical period for bone growth and development, is associated with long-lasting 
improvements in bone health. In the current study, we have therefore used a rat model of maternal 
n3FA supplementation to determine the effects of maternal n3FA dietary supplementation during 
pregnancy and lactation on offspring endochondral bone formation, bone structure and volume, bone 




METHODS AND MATERIALS 
 
Animals and Diets 
Twenty-one female and eight male Albino Wistar rats, weighing between 200-250g, were individually 
caged under a 12 hour light/ 12 hour dark cycle at a room temperature of 25°C.  Female rats were 
acclimatised to a diet designed with a fatty acid composition comparable to a typical Australian 
(Western) diet (40% saturates, 40% monounsaturates, 20% polyunsaturates) (27) (Specialty Feeds, 
Glen Forrest, Western Australia, Australia) for 3 weeks prior to mating to ensure that the fatty acid 
profile of all animals was comparable prior to the dietary intervention. Following this dietary 
acclimatisation, females were mated and allocated into one of two dietary groups: receiving either the 
pre-mating basal diet (5% fat, 0.1% DHA, Control, n=10), or a high n3FA diet (5% fat, 1% DHA, 
n3FA, n=11) throughout pregnancy and lactation. Both diets were isocaloric (20% protein, 59.4% 
carbohydrate and 5% fat by weight). Detailed information on the fatty acid composition of this diet 
has been published previously (28). Food intake was determined 2-3 times weekly during pregnancy 
and lactation and fresh food supplied. Dams were weighed weekly throughout the experimental 
period. 
 
Dams had a natural birth and pups were allowed to suckle from their mothers until weaning.   At 21 
days of age (weaning), pups were separated from their mothers. Male and female from the same litter 
were separated and pups of the same sex in the same litter housed together for the remainder of the 
experiment. All offspring were then fed standard rodent chow ad libitum (20% protein, 59.4% 
carbohydrate and 4.8% fat by weight ) (Rat and Mouse cubes, Specialty Feeds, Glen Forrest, Western 
Australia, Australia) without additional n3FAs added to this standard diet. From birth until weaning, 
pups were weighed every 2 days; after weaning, the offspring was weighed every week.  All animals 
were euthanized by CO2 overdose as stipulated in the Australian Code of Practice for the Care and 
Use of Animals and all procedures were approved by the Animal Ethics Committee of Institute of 
Medical and Veterinary Science, South Australia. 
 
Tissue Collection, Processing, and Measurements of Bone Lengths and Weights 
For assessing effects of maternal n3FA supplementation on offspring’s bone growth, bone mass 
accrual, and adult bone health outcomes, offspring (n=1 from each dam) were euthanized at 3 
separate time-points: 3 weeks (immediately after treatment, newly weaned, childhood), 6 weeks 
(towards the end of rapid growth period or adolescence) and 3 months (12 weeks) (skeletally mature 
adulthood). At the designated time points rats were euthanased with an overdose of CO2 and bloods 
collected via cardiac puncture.  Body length (nose to base of tail) and abdominal circumference were 
also measured.  All organs were dissected and weighed, with special attention paid when collecting 
the long bones: femurs, tibiae and humeri. 
 
The left proximal tibia (1cm length) was dissected, fixed in 10% formalin for 24 hours, decalcified in 
EDTA for 7 days at 4
o
C, routinely processed, paraffin embedded, sectioned at 4µm and stained with 
haematoxylin and eosin (H&E). The right tibia was used for collecting fresh growth plate cartilage 
(by scraping off using a fine scalpel blade), which was then snap frozen in liquid nitrogen and stored 
at -80
o
C. In addition, the proximal metaphysis of the right tibia was also collected and stored frozen at 
-80
o
C for subsequent RNA extraction. All the remaining bone and the humeri were used to collect 
bone marrow samples for cell culture using established methods (29). 
 
Fatty Acid Analysis 
Blood collected via cardiac puncture was centrifuged for obtaining plasma and the remaining red 
blood cell mass was then prepared for fatty acid analysis of red blood cell phospholipids.  Lipid 
extraction, fatty acid methylation and gas chromatographic analysis were performed as previously 
described (28, 30). 
 
Histomorphometric Analysis of Growth Plate and Metaphysis 
On the left tibial sections stained with haematoxylin and eosin (H&E), morphometric measurements 
were conducted as previously described (31) for average growth plate zonal thickness (of the resting, 
proliferative, and hypertrophic zones), height of the primary spongiosa bone, trabecular number and 
thickness within the metaphysis.  Trabecular bone volume BV/TV% was calculated by dividing the 
total trabecular bone area by the total tissue field area. 
 
Metaphysis Osteoblast/Osteoclast Surface Density 
On H&E-stained tibial sections, osteoblasts on the trabecular surface in the secondary spongiosa of 
the metaphysis were counted and were expressed as number of cells per unit length of trabecular bone 
perimeter (cells/mm) as previously described (31). To identify osteoclasts, sections were stained for 
tartrate-resistant acidic phosphatase (TRAP) using established methods (32) (Sigma, NSW, Australia) 
and counterstained with haematoxylin. Multinucleated (>3 nuclei) and TRAP+ cells were counted by 
light microscopy and expressed as number of TRAP+ cells/mm on the trabecular surface in the 
secondary spongiosa. 
 
CFU-f ALP and Mineralisation Assays 
Effects of n3FA supplementation on the osteoprogenitor cell pool in the bone marrow were examined 
ex vivo using bone marrow specimens from the offspring in a Colony Forming Unit- Fibroblast 
(CFU-f) assay as previously described (29, 33).  Briefly, bone marrow cells were plated in duplicate at 
2 x 10
6
 mononuclear cells/well in 6 well plates in complete medium (α-MEM supplemented with 10% 
foetal bovine serum, HEPES, 100μm Lascorbate, 2mM L-glutamine, 100μ/ml penicillin and 100μg/ml 
streptomycin).  Cells were cultured for 14 days and media changed every 3 days. After 14 days 
colonies were fixed with 4% paraformaldehyde and stained for osteoblast differentiation marker 
alkaline phosphatase. (ALP
+





In addition, to assess treatment effects on osteogenic potential of bone marrow stromal cells, cells 
were cultured in osteogenic medium and were assessed for their osteogenesis potential as previously 
described (29).  Briefly, cells were cultured in 24 well plates at a density of 4.75 x 10
4 
cells/well with 
6 wells per animal.  The first 3 wells were fed “mineralisation” media (basal media supplemented 
with 10nM dexamethasone and 10mM β-glycerol-2-phosphate) with the remaining cells cultured in 
unsupplemented basal media.  Cells were re-fed with the respective culture media twice weekly and 
maintained under these conditions for 4 weeks.  Following fixation with formaldehyde, cells were 
washed 3 times in H20 and incubated on a shaker for 20 minutes with 200L/well 40nM alizarin red 
dye. After washing off unincorporated dye, the plate was stored at -20C.  For quantification, the 
incorporated dye was extracted on a shaker with 160L of 10% (v/v) acetic acid, and after being 
neutralised with 40µL of 10% (v/v) ammonium hydroxide, was analysed colorimetrically at 405nm. 
 
Quantitative RT-PCR gene expression analysis 
Real-time RT-PCR was used to assess the relative mRNA expression of major stimulator of osteoclast 
formation and activity (receptor activator of nuclear factor-κB ligand or RANKL) and osteoclast 
formation inhibitor (osteoprotegerin or OPG) (34) as well as tumour necrosis factor (TNF-a) and 
interleukin-6 (IL-6) (two inflammatory cytokines known to promote osteoclastogenesis). In addition, 
expression of osteogenesis-related gene osterix and bone matrix protein, osteocalcin mRNA were also 
determined. Total RNA from frozen metaphyseal bone samples were isolated using TRIZOL solution 
(Sigma, NSW, Australia). Two micrograms of metaphyseal RNA were then reverse transcribed into 
cDNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems, CA) according to the 
manufacturer’s instructions. This cDNA was used to determine the mRNA expression for the genes of 
interest by quantitative real-time PCR as previously described (35) using gene specific primers 
detailed in Table 2 (primers designed using Primer Express® software v2.0, Applied Biosystems, CA) 
and cyclophilin-A (CycA) as the housekeeping control loading gene. SYBR green PCR assays for 
each target molecule and internal reference CycA were performed in duplicate on these cDNA 
samples in a 10 μl reaction using the Applied Biosystems 7500 FAST 96-well PCR machine. From 
the amplification curves, relative expression was calculated using the comparative Ct (2
-Ct) method, 
with Cyclophilin A serving as the endogenous control.  
 
Statistical Analysis 
Data are presented as means ± SEM.  The effects of maternal n3FA supplementation, during 
pregnancy and lactation, on offspring erythrocyte fatty acid composition and RT-PCR expression data 
were determined by Student’s unpaired t-test.  Effects of supplementation on maternal weight change 
during pregnancy and lactation, and postnatal weight gain in male and female offspring was 
determined using an ANOVA with repeated measures.  When significant levels (p<0.05) were 
achieved, a Tukey's Post Hoc test was performed. In tables and figures, *, **, and *** represent 
p<0.05, p<0.01, and p<0.001, respectively. 
RESULTS 
 
Effects of maternal n3FA supplementation on maternal parameters  
Before mating, the weights of the mothers were comparable between the two dietary groups. Prior to 
commencement of supplementation, there were no differences in n3FA content in maternal 
erythrocytes between the dams fed on the two diets (Basal, 6.01 ± 0.09%; n3FA, 6.40 ± 0.33%).  At 
weaning, the levels of DHA (Basal, 2.30 ± 0.11%; n3FA, 3.68 ± 0.22%) and total n3FAs (Basal, 3.81 
± 0.04%; n3FA, 5.42 ± 0.26%) were significantly higher in the n3FA supplemented dams than in the 
basal control (P<0.001).  There was no effect of maternal n3FA supplementation on maternal weight 
gain during pregnancy or weight loss during lactation, and there were no differences in maternal body 
weight at the end of lactation between the basal and n3FA groups as previously reported (28).  
Maternal omega-3 intake had no effects on maternal food intake during either pregnancy or lactation 
(28). 
 
Effects of maternal n3FA supplementation on pregnancy outcomes and offspring fatty acid 
status 
Maternal supplementation with n3FA during pregnancy and lactation resulted in increased offspring 
erythrocyte DHA (p<0.001) and total n3FA levels (p<0.001) at 3-weeks of age (Figure 1A, B).  
Despite n3FA supplementation being ceased at weaning, increased DHA and total n3FA levels 
persisted until 6-weeks of age (p<0.001), but had returned to control levels by 3-months of age.  
Interestingly, 3-week old females offspring from n3FA supplemented dams exhibited a marked 
increase in erythrocyte levels of arachidonic acid (AA) (Basal: 18.90 ± 0.45 vs n3FA: 20.86 ± 0.60; 
P=0.044) and linoleic acid (LA) (Basal:18.90 ± 0.45 vs n3FA: 20.86 ± 0.60; P=0.044) when compared 
to basal females and n3FA supplemented males (n3FA female: 20.86 ± 0.60 vs n3FA male 17.55 ± 
0.69; P=0.028).  Levels of AA and LA returned to basal levels by 6-weeks of age (data not shown). 
 
As reported previously (28), maternal n3FA supplementation did not alter body length or body weight 
of the offspring at the ends of critical growth periods (3 week, 6 week and 3 months of age).   n3FA 
supplementation also did not affect the length of gestation, litter size or mean pup birth weight (28).  
Male/females offspring ratios were also comparable (28). 
 
Effect of maternal n3FA supplementation on offspring growth plate structures  
Histological analysis of proximal tibial bones from basal (Figure 2A) and n3FA supplemented 
offspring (Figure 2B) revealed that while n3FA supplementation did not affect overall thickness of the 
growth plate at any time point (Figure 2C), n3FA supplementation significantly increased the height 
of the resting zone in both male (p<0.02) and female (p<0.01) offspring at 3-weeks of age (Figure 
2D).  There was no effect of n3FA supplementation on the thickness of the resting zone at either 6 
weeks or 3 months of age. There was also no effect of maternal n3FA supplementation on the 
morphometric features of the proliferative zone or hypertrophic zone irrespective of age or sex (data 
not shown). 
 
Effect of maternal n3FA supplementation on structural changes in the metaphysis of offspring 
Examination of H&E stained sections of the proximal tibia showed that the primary spongiosa height 
in both male and female offspring was unaffected by maternal dietary n3FA supplementation (results 
not shown). Further histological analysis of the trabeculae in the secondary spongiosa  showed little 
variability across the diets or sexes; however, when compared to the basal group, 3-week old male, 
but not female, offspring of dams supplemented with n3FA exhibited an increased bone volume/tissue 
volume ratio (BV/TV%) (Figure 3A, B, C).  The increase in BV/TV% was attributed to an increase in 
both the average trabecular thickness (p<0.05; Figure 3D) and an increase in trabecular number in the 
n3FA 3-weekold male offspring compared to Controls (p<0.001; Figure 3E). 
 
Changes in osteoclast density and expression of osteoclastogenesis regulatory genes in the 
metaphysis 
 Consistent with the increased BV/TV%, 3-week old male offspring of n3FA dams exhibited a 
decreased number of osteoclasts per millimetre of trabecular bone surface (p<0.05; Figure 4A, B, C).  
Furthermore, RT-PCR gene expression analysis revealed a significant decrease in mRNA expression 
of  the critical osteoclast formation gene, RANKL (P<0.01; Figure 4D) but no change in 
osteoclastogenesis inhibitor, OPG (P>0.05; Figure 4E) in these offspring.  Thus, the RANKL/OPG 
ratio was significantly decreased in 3-week old n3FA supplemented male offspring compared to 
controls (P<0.05; results not shown).  mRNA expression of pro-inflammatory cytokines TNF-a 
(P<0.05; Figure 4F) and IL-6 (P<0.05; Figure 4G) were also decreased in 3-week old male offspring 
of n3FA supplemented dams,  indicating that maternal supplementation with n3FA decreases 
expression of signals important for osteoclast formation and activity. There was no effect of maternal 
n3FA supplementation on any of these measures in 3-week female offspring or in 6-week or 3-month 
old offspring of either sex. 
 
Changes in osteoblast density in the metaphysis 
Previously n3FA supplementation has not only been shown to affect osteoclast number and activity, 
but also the number of bone forming osteoblasts (36).  To examine whether the increase in BV/TV% 
in the 3-week old male offspring of n3FA-supplemented dams were attributed to alterations in 
osteoblast formation and density, osteoblast numbers on bone trabecular surfaces of the 3-week old 
male offspring were also analysed. Analysis of H&E stained sections of secondary spongiosa showed 
that n3FA-supplemented offspring had an increased number of osteoblasts lining the bony trabeculae 
(p<0.05) compared to controls (Fig. 5A, B, C).  Consistent with the higher osteoblast density, 
offspring in the n3FA group exhibited increased mRNA expression of osterix, a transcription factor 
essential for osteoblast differentiation and maturation (P<0.05; Figure 5D). There was no effect of 
maternal n3FA supplementation on mRNA expression of the bone matrix protein osteocalcin in the 
offspring at any time point (Figure 5E). 
 
Effects of maternal n3FA supplementation on ex vivo osteogenic potential 
In order to examine the effects of n3FA supplementation on osteoblast differentiation from bone 
marrow stromal progenitor cells, an ex vivo CFU-F assay plus ALP staining was performed with bone 
marrow stromal cells isolated from the offspring.   The number of ALP
+
 colonies (or number of 
osteoprogenitor cells) was significantly increased in 3-week old male offspring of n3FA 
supplemented dams compared to the controls (P<0.01; Figure 5F). In addition, as a measure of the 
treatment effects on late stage osteogenic potential of the bone marrow stromal cells, a mineralisation 
assay with the bone marrow cells showed that maternal n3FA supplementation resulted in an increase 
in the mineralising potential of bone marrow stromal cells in the 3-week old male offspring compared 
to the basal diet control (Figure 5G). 
 
DISCUSSION 
Recently it has become increasingly apparent that nutrient supply before birth and in early infancy is 
important for achieving optimal bone growth and peak bone mass during childhood/adolescence. 
Although n3FA has been previously shown to improve bone deposition and bone mass in growing 
animals and in adult humans, no previous studies have assessed whether supplementing the maternal 
diet with n3FA improves bone health in the offspring. Here we have shown that maternal n3FA 
supplementation during pregnancy and lactation leads to elevated n3FA RBC concentrations in the 
offspring. This increase resulted in several positive outcomes within the metaphysis of long bones in 
3-week old male offspring.  Interestingly, the beneficial effects in the bone were found to be quite 
short lived, suggesting that whilst there may be short-term benefits of increased perinatal exposure to 
n3FA on bone growth and development in males, the effects are unlikely to be maintained into 
adolescence and adulthood when these offspring are weaned onto a standard (low n3FA) chow diet.  
  
Maternal n3FA supplementation increases omega-3 index in the offspring 
It is known that eicosapentaenoic acid (EPA) and DHA are never completely absent from breast milk, 
and the level is largely determined by the mother’s diet (37, 38). This was apparent in the current 
study as erythrocyte EPA, DHA and total omega-3 LCPUFA concentrations in n3FA supplemented 
pups were significantly higher than in the control group.  It is important to note that these levels 
remained elevated up to 6 weeks of age, even though both control and n3FA groups had been 
consuming standard rat chow since weaning. This therefore suggests that fatty acids incorporated into 
erythrocyte phospholipids before and during the suckling period can be retained after weaning and 
these have the potential to have prolonged biological effects (28).  As it has been previously shown 
that it takes 2-3 weeks for dietary fat composition changes to alter erythrocyte fatty acid composition, 
this result was not unexpected (39).  
 
Can early exposure to n3FAs promote bone development? 
Whilst previous studies have reported beneficial effects of n-3 LCPUFA supplementation on bone 
strength in adolescent and adult animals, our current study showed that n3FA supplementation did not 
appear to alter the structure of the region of the bone responsible for determining the future length and 
shape of the mature bone – the epiphyseal plate/growth plate. While there is very little data 
concerning the effects of n3FAs on specific regions of growth plate, studies investigating the effects 
of n3FAs on chick epiphyseal growth plate cartilage have indicated that dietary lipids are able to 
affect cartilage metabolism  (40). In this study, treating chick chondrocytes with the omega-6 (n6) 
PUFA, linoleic acid (LA), resulted in  decreased collagen synthesis, whereas treatment with n3FAs 
increased collagen synthesis (40). The epiphyseal plate of the growing chick has also been reported to 
be able to selectively incorporate certain dietary fatty acids (41). In the current study, maternal 
supplementation with n3FAs did not affect the overall height of the growth plate of the offspring. 
Interestingly, the size of the resting zone, the region comprising of undifferentiated or resting cartilage 
cells, was increased in both male and female 3-week old offspring of n3FA supplemented dams. The 
functional significance of this change is unclear, however it is unlikely to have translated into any 
long term effects on bone health, as all parameters of the growth plate were again comparable by 6-
weeks of age.  
 
The n3FA have long been implicated in bone homeostasis (20, 24, 42-44) with increasing evidence 
that lack of n-3FA can induce bone loss (22, 45), while dietary n3FA supplementation may promote 
bone formation (20, 22). In the current study we have shown that maternal supplementation with 
n3FAs during pregnancy and lactation did not result in any increases in the height of primary 
spongiosa bone, the region containing woven trabecular bone that is newly converted from the 
calcified hypertrophic growth plate cartilage  (46).  However, 3-week old male offspring of n3FA 
supplemented dams had an increased number and thickness of trabeculae within the secondary 
spongiosa resulting in an overall increase in the ratio of bone volume to total volume (BV/TV%), 
accompanied by a significant decrease in the number of resorptive osteoclasts. This result is consistent 
with existing studies which have demonstrated the ability of n3FA to inhibit osteoclast number and 
function both in vitro (47) and in vivo (19, 21, 48), and suggests that increasing the supply of n3FA 
during the early period of bone development has the potential to promote bone formation.   
 
There are currently two known mechanisms by which n3FA inhibit osteoclastogenesis. Firstly, these 
FA can act indirectly by increasing osteoblast number and RANKL expression and secondly, via a 
more direct method, PUFA metabolites (ie prostaglandins or PGs) acting to inhibit osteoclast 
progenitors and osteoclast formation (47). The results of the present study, consistent with the 
literature, have shown that supplementation with n3FA during pregnancy and lactation decreases the 
number of osteoclasts present on the bone surface in the 3-week male offspring. This appeared to be 
due to an increased mRNA expression of OPG, which has an important role in inhibiting 
osteoclastogenesis (49, 50) and suppressing osteoclast survival (51), coupled with a simultaneous 
downregulation of the expression of RANKL mRNA, which is critical for osteoclast formation and 
differentiation, in the metaphysis of the growing offspring. Consistent with previous studies in adult 
rats which showed that n3FA supplementation inhibits osteoclast formation/activation and bone 
resorption by suppressing the expression of proinflammatory cytokines and osteoclastogenic factors 
(19), the current study showed that maternal n3FA supplementation had also decreased the expression 
of pro-inflammatory cytokines, TNF-a and IL-6, in the 3-week old male offspring.  
 
Not only has n3FA supplementation been shown to suppress formation of osteoclasts, but it has also 
been associated with enhanced activity of bone forming osteoblasts (19, 43), such that the increase in 
BV/TV% in the present study could be due not only to a reduction in osteoclastogenesis, but also 
enhanced osteogenesis. In support of the relationship between dietary PUFAs and bone metabolism, it 
has previously been reported that feeding post-weaning male Fisher rats DHA substantially increased 
bone marrow cell number (52). As the bone marrow consists of precursor cells including 
mesenchymal stem cells, it is possible that the higher number of marrow cells could translate into an 
increase in the osteoblastogenic potential (53). Runx2 or cbf-α1, an essential transcription factor for 
the commitment of mesenchymal cells to the osteogenic lineage, has  previously been reported to be 
increased in fetal rat calvarial cells when stimulated with n3FA (EPA)  (43). In the present study, we 
showed that maternal n3FA supplementation could enhance the differentiation of pre-osteoblast like 
cells into mature mineralizing osteoblasts in the offspring with the ability to form mineralized 
extracellular matrix.   
 
In the literature there is increasing interest in the concept of programming, the idea that "a stimulus or 
insult during a critical or sensitive period of development can have long-term or lifetime effects" (4). 
There are numerous studies investigating early nutrition “programming” in animals but now 
randomized intervention trials with long-term follow-up are appearing, showing nutrition in early life 
has a major impact on health into early adulthood, including cardiovascular disease risk and bone 
health (54, 55).  The ability of particular treatments to induce long-term effects is dependent on both 
the duration and timing during development when it is applied. For example, Jones et al (55) found a 
positive correlation between duration of breastfeeding and increased bone mineral density at 8 years 
of age,  and  concluded  that breastfeeding for less than 3 months was not associated with increased 
bone mass at any site in the children. This suggests, therefore, that the lack of a sustained effect of 
maternal n3FA supplementation on structure and function of bone in the offspring, may have been 
because the duration of supplementation in the current study was insufficient to maintain the positive 
bone changes, the timing of supplementation was not right, or a combination of both these factors.   It 
is also likely that the children in the few studies concerning early nutrition and later bone mass 
received sufficient amounts of n3FAs from their diets post breastfeeding. In contrast, the rats in the 
current study were all weaned onto a standard rat chow which contained very low levels of EPA and 
DHA, and n3FA levels in the offspring of n3FA supplemented dams had returned to the levels seen in 
control offspring by 3 months of age.  This implies that any n3FA that were stored in offspring tissues 
at the end of the intervention (weaning) were likely depleted as dietary intake was no longer able to 
meet requirements for n3FAs throughout the rest of the critical growth period, and hence lasting 
effects were not observed. It will be important in future studies to determine whether these positive 
effects are maintained if the offspring are maintained on a high n3FA diet post-weaning. 
 
Offspring gender difference in the bone benefit effects of maternal n3FA supplementation 
This study has shown that there is a significant difference between the effects of n3FA maternal 
supplementation between male and female offspring. The slightly higher levels of DHA (P=0.055) 
and increased AA levels (P=0.028) in the female supplemented offspring, when compared to their 
male counterparts, could be due to gender differences in sex hormone status and therefore different 
hormonal regulation of PUFA metabolism. This is supported by clinical data, which shows that 
estrogens, but not androgens, can increase concentrations of AA and DHA in the blood lipids of 
patients treated with sex hormone steroids (56, 57). Other studies have also shown that female rats 
exhibit higher DHA levels in their livers (58) and replete their DHA status more readily than males 
(59). The molecular, cellular and bone volume differences seen between our 3-week old supplemented 
male and female offspring are possibly due to the elevated levels of AA present in the female 
offspring. AA and its metabolite PG-E2 are proinflammatory and several studies have established the 
significance of PG-E2 in osteoclast formation and bone resorption (60-62) . However, DHA is able to 
inhibit PG-E2 synthesis (63) perhaps by replacing AA in the cell membrane and therefore limiting the 
amount of AA available for PG-E2 production (64).  It is possible that the increased levels of AA in 
the female offspring provide increased competition with the n3FAs and hence could be dampening the 
positive effects that were seen in the n3FA supplemented male offspring. 
   
Summary 
We have therefore reported that maternal n3FA supplementation during pregnancy and lactation 
translates into elevated DHA, EPA and total LC-PUFA RBC concentrations in all offspring at 3- and 
6-weeks of age, and is associated with an increased number of osteoblasts and a decreased osteoclast 
density, and consequently a higher volume of trabecular bone only in 3-week old male, but not 
female, offspring and that these effects are not maintained at 6-weeks or 3 months of age. These 
results, as in some previous reports, have established that there are sex-dependent differences in the 
beneficial effects of n3FA and indicate that further research is needed in order to derive sex-specific 
nutritional/supplement recommendations.  In addition, this study has demonstrated that although 
n3FA supplementation throughout pregnancy and lactation can exert positive effects on early bone 
development, at least in males, the positive effects diminish once the supplementation has ceased and 
n3FA tissue stores have returned to control levels. Overall, the results of this study suggest that 
increasing the supply of dietary n3FA during the prenatal and early postnatal period has no lasting 
benefits for bone health in the offspring, and that the maintenance of a high intake of n3FA post-
weaning is likely to be required in order to achieve lasting effects.  
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Figure 1: Effects of maternal dietary n3FA supplementation during pregnancy and 
lactation on erythrocyte n3FA and LC-PUFA concentrations of offspring. n3FA 
supplementation increased red blood cell concentrations of DHA (A) and total LC-PUFAs (B) 
in 3-week and 6-week old offspring (p<0.001) which returned to control levels by 3-months of 
age.  
 
Figure 2: Effects of maternal dietary n3FA supplementation during pregnancy and 
lactation on the total thickness and individual zonal heights of growth plate in proximal 
tibia of offspring.   H&E section of control (A) and n3FA supplemented (B) offspring rat at 
weaning (21d). The dashed lines in A and B arbitrarily separate the three individual growth 
plate zones (Resting, Rz; Proliferative, Pz; Hypertrophic, Hz) (Bar = 200m), and the sum of 
individual zonal heights amounts to the total growth plate thickness (C). No differences in 
zonal heights were detected, with exception to the resting zone which was increased in both 
male and female offspring of n3FA-supplemented dams (P<0.001) (D). 
 
Figure 3: Effects of maternal dietary n3FA supplementation during pregnancy and 
lactation on the trabecular bone volume and architecture in the proximal tibial 
metaphysis of the offspring. H&E stained sections of control metaphysis (A) and n3FA 
supplemented metaphysis (B) at weaning  (Bar = 200μm). Histological analysis shows an 
increase in bone volume/tissue volume (BV/TV%) in male but not female offspring (C), 
which was associated with increases in trabecular thickness (D) and trabecular number (E). 
 
Figure 4: Osteoclast density on trabecular bone surface and mRNA expression of 
important regulatory genes of osteoclastogenesis in the metaphysis of control and n3FA 
supplemented offspring.   TRAP- stained sections of control metaphysis (A) and n3FA 
supplemented metaphysis (B) (Bar = 100μm). Osteoclasts are TRAP-positively stained cells 
adhering to the trabecular surface, and numbers counted and expressed as TRAP+ cells/mm 
trabecular perimeter surface (C).  Relative expression was calculated using the comparative Ct 
(2
-Ct) method, with Cyclophilin A serving as the endogenous control: RANKL (D), OPG (E), 
TNF-alpha (F), Interleukin-6 (G). 
 
Figure 5: Osteoblast density, mRNA expression of important osteogenic genes and in 
vitro analysis of osteogenic potential in the metaphysis of 3-week old control and n3FA 
supplemented male offspring.   Osteoblasts were identified and counted via routine H&E 
staining in sections of control (A) and n3FA supplemented metaphysis (B) (Bar = 100μm). 
Osteoblasts were identified as cuboidal cells lining that metaphyseal surface and expressed as 
cells/mm trabecular perimeter surface (C). Relative real-time RT-PCR analysis of mRNA 
expression of important osteogenic genes osterix (D) and osteocalcin (E) expression was 
calculated using the comparative Ct (2
-Ct) method, with Cyclophilin A serving as the 
endogenous control:. In vitro analysis of osteogenic potential was carried out via colony 
forming unit -fibroblast assay, expressed as ALP+ colonies per well (F) and colormetric 
analysis of Alizarin Red staining after stimulation with osteogenic media (G).   
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